Morgan Stanley Reiterates Underweight Rating on GlaxoSmithKline (GSK:LN) (GSK): "risk/reward skewed to downside"

March 10, 2026 12:04 PM

Morgan Stanley analyst Sarita Kapila reiterated an Underweight rating and GBp1,700.00 price target on GlaxoSmithKline ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found